Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
Vaxcyte (PCVX) has appointed Dr. Olivier Brandicourt, former CEO of Sanofi S.A., to its Board of Directors. Dr. Brandicourt brings extensive biopharmaceutical expertise, particularly in global vaccine market commercial strategy and execution. During his tenure at Sanofi, he strengthened the company's position as a leading commercial vaccine company. His appointment comes at a crucial time as Vaxcyte advances toward potential global commercialization of its pneumococcal conjugate vaccine (PCV) candidates.
The company also announced that Dr. Peter Hirth, who has served on the Board since 2016, will conclude his tenure in June. Vaxcyte's carrier-sparing platform aims to address unmet needs in bacterial disease prevention and contribute to combating antimicrobial resistance.
Vaxcyte (PCVX) ha nominato il dottor Olivier Brandicourt, ex CEO di Sanofi S.A., nel suo Consiglio di Amministrazione. Il dottor Brandicourt apporta una vasta esperienza nel settore biofarmaceutico, in particolare nella strategia commerciale e nell'esecuzione nel mercato globale dei vaccini. Durante il suo mandato in Sanofi, ha rafforzato la posizione dell'azienda come leader nel settore dei vaccini commerciali. La sua nomina avviene in un momento cruciale, mentre Vaxcyte si avvicina alla potenziale commercializzazione globale dei suoi candidati vaccini coniugati antipneumococcici (PCV).
L'azienda ha inoltre annunciato che il dottor Peter Hirth, membro del Consiglio dal 2016, concluderà il suo mandato a giugno. La piattaforma carrier-sparing di Vaxcyte mira a rispondere a bisogni insoddisfatti nella prevenzione delle malattie batteriche e a contribuire nella lotta contro la resistenza antimicrobica.
Vaxcyte (PCVX) ha nombrado al Dr. Olivier Brandicourt, ex CEO de Sanofi S.A., para su Junta Directiva. El Dr. Brandicourt aporta una amplia experiencia en biofarmacéutica, especialmente en la estrategia comercial y ejecución en el mercado global de vacunas. Durante su gestión en Sanofi, fortaleció la posición de la empresa como líder en vacunas comerciales. Su nombramiento llega en un momento clave, ya que Vaxcyte avanza hacia la posible comercialización global de sus candidatos a vacunas conjugadas neumocócicas (PCV).
La compañía también anunció que el Dr. Peter Hirth, que ha formado parte de la Junta desde 2016, concluirá su mandato en junio. La plataforma carrier-sparing de Vaxcyte busca cubrir necesidades no satisfechas en la prevención de enfermedades bacterianas y contribuir a combatir la resistencia antimicrobiana.
Vaxcyte (PCVX)는 전 Sanofi S.A. CEO인 올리비에 브란디쿠르 박사를 이사회에 임명했습니다. 브란디쿠르 박사는 특히 글로벌 백신 시장의 상업 전략 및 실행에 대한 폭넓은 바이오제약 전문 지식을 보유하고 있습니다. 그는 Sanofi 재임 기간 동안 회사의 상업용 백신 분야 리더십을 강화했습니다. 그의 임명은 Vaxcyte가 폐렴구균 접합 백신(PCV) 후보의 전 세계 상업화를 향해 나아가는 중요한 시점에 이루어졌습니다.
또한 회사는 2016년부터 이사회에서 활동해 온 피터 허스 박사가 6월에 임기를 마칠 것이라고 발표했습니다. Vaxcyte의 캐리어-스페어링 플랫폼은 세균성 질환 예방의 미충족 수요를 해결하고 항생제 내성 문제에 대응하는 데 기여하는 것을 목표로 합니다.
Vaxcyte (PCVX) a nommé le Dr Olivier Brandicourt, ancien PDG de Sanofi S.A., au sein de son conseil d'administration. Le Dr Brandicourt apporte une vaste expertise biopharmaceutique, notamment dans la stratégie commerciale et l'exécution sur le marché mondial des vaccins. Pendant son mandat chez Sanofi, il a renforcé la position de l'entreprise en tant que leader commercial dans le domaine des vaccins. Sa nomination intervient à un moment crucial, alors que Vaxcyte progresse vers une possible commercialisation mondiale de ses candidats vaccins conjugués pneumococciques (PCV).
L'entreprise a également annoncé que le Dr Peter Hirth, membre du conseil depuis 2016, terminera son mandat en juin. La plateforme carrier-sparing de Vaxcyte vise à répondre aux besoins non satisfaits dans la prévention des maladies bactériennes et à contribuer à la lutte contre la résistance antimicrobienne.
Vaxcyte (PCVX) hat Dr. Olivier Brandicourt, den ehemaligen CEO von Sanofi S.A., in seinen Vorstand berufen. Dr. Brandicourt bringt umfassende Erfahrung in der Biopharma-Branche mit, insbesondere in der globalen kommerziellen Strategie und Umsetzung im Impfstoffmarkt. Während seiner Zeit bei Sanofi stärkte er die Position des Unternehmens als führender Anbieter kommerzieller Impfstoffe. Seine Ernennung erfolgt zu einem entscheidenden Zeitpunkt, da Vaxcyte auf die mögliche globale Kommerzialisierung seiner Pneumokokken-Konjugat-Impfstoffkandidaten (PCV) hinarbeitet.
Das Unternehmen gab zudem bekannt, dass Dr. Peter Hirth, der seit 2016 im Vorstand tätig ist, sein Mandat im Juni beenden wird. Die carrier-sparing Plattform von Vaxcyte zielt darauf ab, ungedeckte Bedürfnisse in der Prävention bakterieller Erkrankungen zu adressieren und zur Bekämpfung der antimikrobiellen Resistenz beizutragen.
- Appointment of former Sanofi CEO brings significant commercial vaccine market expertise
- Strategic addition to support global commercialization of PCV candidates
- Strengthens leadership team with experienced pharmaceutical executive
- None.
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
“We are thrilled to welcome Olivier to Vaxcyte’s Board of Directors,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market. During his time as the CEO of Sanofi, he further bolstered the company’s standing as one of the world’s leading commercial vaccine companies. His strategic insight and operational leadership will be instrumental as we advance toward the potential global commercialization of our pneumococcal conjugate vaccine (PCV) candidates. Separately, I would like to extend our sincere thanks to Dr. Peter Hirth, who has served on the Board since 2016 and will conclude his tenure in June. We are deeply grateful for his years of dedicated service and myriad contributions to Vaxcyte during a defining period in our growth.”
“Vaxcyte’s carrier-sparing platform represents a highly differentiated and scientifically compelling approach, with the potential to address some of the most pressing unmet needs in the prevention of bacterial diseases,” said Dr. Brandicourt. “I’m honored to join the Board at such a pivotal time and look forward to working with the team as the Company continues to advance its PCV candidates toward potential commercialization. By broadening protection against invasive pneumococcal disease, Vaxcyte is not only aiming to set a new standard of care—it is also contributing to the global effort to combat antimicrobial resistance, a pervasive public health threat driven by the overuse of antibiotics.”
About Dr. Brandicourt
Dr. Brandicourt is a distinguished executive in the biopharmaceutical industry. He is currently a Senior Advisor at Blackstone Life Sciences and serves on the boards of Alnylam Pharmaceuticals, Inc., AvenCell Therapeutics, Inc., BeOne Medicines Ltd. and Dewpoint Therapeutics, Inc.
He was the CEO of Sanofi S.A. from 2015 to 2019, where he was instrumental in advancing the company’s vaccine portfolio through the acquisition of Protein Sciences and its recombinant influenza vaccine, and the CEO of Bayer HealthCare AG from 2013 to 2015. Dr. Brandicourt also spent 13 years at Pfizer Inc., including as a member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units. Additionally, he served in a series of leadership positions, including heading Pfizer’s Global Specialty and Global Primary Care business units.
Dr. Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine and holds a Master’s Degree in Biology and an Advanced Degree in Cellular and Immunological Pathophysiology. He is an Honorary Fellow of the Royal College of Physicians in London and has been a director of the National Committee on U.S.-China Relations since 2012.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s carrier-sparing platform and PCV candidates; the potential global commercialization of its PCV candidates; the ability to improve upon the standard-of-care and combat antimicrobial resistance; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Yearly Report on Form 10-K filed with the SEC on February 25, 2025 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
Who is Dr. Olivier Brandicourt and why did Vaxcyte (PCVX) appoint him to the Board?
What is Vaxcyte's (PCVX) main focus in vaccine development?
Who is leaving Vaxcyte's (PCVX) Board of Directors?
What is the significance of Vaxcyte's (PCVX) carrier-sparing platform?
